MedTrace Logo

Intravenous Recombinant Human Prourokinase for Acute Medium Vessel Occlusion 4.5-24 Hours After Ischemic Stroke

NCT07776873 · Status: NOT_YET_RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 616

Last updated 2026-08-20

No results posted yet for this study

Summary

The HOPE-MeVO study aims to evaluate the efficacy and safety of intravenous recombinant human prourokinase (rhPro-UK) in patients with acute ischemic stroke due to medium vessel occlusion presenting 4.5 to 24 hours after stroke onset or last known well. Eligible patients will be selected based on CT perfusion imaging and randomly assigned to receive rhPro-UK plus standard medical treatment or standard medical treatment alone. The primary objective is to determine whether rhPro-UK improves functional outcome at 90 days.

Conditions

  • Acute Ischemic Stroke

Interventions

DRUG

Recombinant Human Prourokinase for Injection (rhPro-UK)

Recombinant human prourokinase (rhPro-UK) is administered intravenously at a fixed total dose of 35 mg: a 15 mg intravenous bolus over 3 minutes, followed by a 20 mg intravenous infusion over 30 minutes.

OTHER

Standard medical treatment (SMT)

Standard medical treatment is individualized according to the 2026 AHA/ASA Guideline for the Early Management of Patients With Acute Ischemic Stroke.

Sponsors & Collaborators

  • The First Affiliated Hospital of Anhui Medical University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-09-06
Primary Completion
2029-06-30
Completion
2029-06-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07776873 on ClinicalTrials.gov